Core Viewpoint - Rapport Therapeutics, Inc. has announced a public offering of 9,615,385 shares at a price of $26.00 per share, aiming to raise approximately $250 million in gross proceeds before expenses [1][3]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [5]. - The company utilizes a RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, which allows for a differentiated approach in drug discovery [5]. - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for conditions such as drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [5]. Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,442,307 shares at the public offering price [1]. - The offering is expected to close around September 11, 2025, pending customary closing conditions [1]. - Goldman Sachs, Jefferies, TD Cowen, and Stifel are acting as joint book-running managers for the offering [2].
Rapport Announces Pricing of Public Offering of Common Stock